Biogen shares soar 13% on successful Alzheimer's drug trial
July 06, 2018 at 08:17 AM EDT
Biogen and Eisai announced positive results from a Phase II study with BAN2401, an Alzheimer's disease drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|